Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1865–1870. doi: 10.1054/bjoc.2001.2168

A phase II trial of marimastat in advanced pancreatic cancer

J D Evans 1, A Stark 2, C D Johnson 3, F Daniel 4, J Carmichael 5, J Buckels 1, C W Imrie 2, P Brown 6, J P Neoptolemos 1,7
PMCID: PMC2364022  PMID: 11747327

Abstract

Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: pancreatic cancer, matrix metalloproteinases, marimastat, toxicity

Full Text

The Full Text of this article is available as a PDF (65.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bramhall S. R., Allum W. H., Jones A. G., Allwood A., Cummins C., Neoptolemos J. P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995 Jan;82(1):111–115. doi: 10.1002/bjs.1800820137. [DOI] [PubMed] [Google Scholar]
  2. Bramhall S. R., Neoptolemos J. P., Stamp G. W., Lemoine N. R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol. 1997 Jul;182(3):347–355. doi: 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  3. Bramhall S. R., Rosemurgy A., Brown P. D., Bowry C., Buckels J. A., Marimastat Pancreatic Cancer Study Group Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001 Aug 1;19(15):3447–3455. doi: 10.1200/JCO.2001.19.15.3447. [DOI] [PubMed] [Google Scholar]
  4. Bramhall S. R., Stamp G. W., Dunn J., Lemoine N. R., Neoptolemos J. P. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer. 1996 Apr;73(8):972–978. doi: 10.1038/bjc.1996.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brenner D. A., O'Hara M., Angel P., Chojkier M., Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature. 1989 Feb 16;337(6208):661–663. doi: 10.1038/337661a0. [DOI] [PubMed] [Google Scholar]
  6. Brown P. D., Bloxidge R. E., Stuart N. S., Gatter K. C., Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993 Apr 7;85(7):574–578. doi: 10.1093/jnci/85.7.574. [DOI] [PubMed] [Google Scholar]
  7. Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
  8. Campo E., Merino M. J., Tavassoli F. A., Charonis A. S., Stetler-Stevenson W. G., Liotta L. A. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol. 1992 May;16(5):500–507. doi: 10.1097/00000478-199205000-00009. [DOI] [PubMed] [Google Scholar]
  9. Glimelius B., Hoffman K., Sjödén P. O., Jacobsson G., Sellström H., Enander L. K., Linné T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996 Aug;7(6):593–600. doi: 10.1093/oxfordjournals.annonc.a010676. [DOI] [PubMed] [Google Scholar]
  10. Greene J., Wang M., Liu Y. E., Raymond L. A., Rosen C., Shi Y. E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996 Nov 29;271(48):30375–30380. doi: 10.1074/jbc.271.48.30375. [DOI] [PubMed] [Google Scholar]
  11. Gress T. M., Müller-Pillasch F., Lerch M. M., Friess H., Büchler M., Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 1995 Aug 9;62(4):407–413. doi: 10.1002/ijc.2910620409. [DOI] [PubMed] [Google Scholar]
  12. Harris E. D., Jr Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990 May 3;322(18):1277–1289. doi: 10.1056/NEJM199005033221805. [DOI] [PubMed] [Google Scholar]
  13. Jones L., Ghaneh P., Humphreys M., Neoptolemos J. P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci. 1999 Jun 30;880:288–307. doi: 10.1111/j.1749-6632.1999.tb09533.x. [DOI] [PubMed] [Google Scholar]
  14. Mallinson C. N., Rake M. O., Cocking J. B., Fox C. A., Cwynarski M. T., Diffey B. L., Jackson G. A., Hanley J., Wass V. J. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J. 1980 Dec 13;281(6255):1589–1591. doi: 10.1136/bmj.281.6255.1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mori M., Barnard G. F., Mimori K., Ueo H., Akiyoshi T., Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer. 1995 Mar 15;75(6 Suppl):1516–1519. doi: 10.1002/1097-0142(19950315)75:6+<1516::aid-cncr2820751522>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  16. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 1995 Aug 1;55(15):3263–3266. [PubMed] [Google Scholar]
  17. Pajouh M. S., Nagle R. B., Breathnach R., Finch J. S., Brawer M. K., Bowden G. T. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol. 1991;117(2):144–150. doi: 10.1007/BF01613138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Palmer K. R., Kerr M., Knowles G., Cull A., Carter D. C., Leonard R. C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994 Jun;81(6):882–885. doi: 10.1002/bjs.1800810629. [DOI] [PubMed] [Google Scholar]
  19. Porte H., Chastre E., Prevot S., Nordlinger B., Empereur S., Basset P., Chambon P., Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995 Feb 20;64(1):70–75. doi: 10.1002/ijc.2910640114. [DOI] [PubMed] [Google Scholar]
  20. Sellers A., Murphy G., Meikle M. C., Reynolds J. J. Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases. Biochem Biophys Res Commun. 1979 Mar 30;87(2):581–587. doi: 10.1016/0006-291x(79)91834-5. [DOI] [PubMed] [Google Scholar]
  21. Smith F. P., Hoth D. F., Levin B., Karlin D. A., MacDonald J. S., Woolley P. V., 3rd, Schein P. S. 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer. 1980 Nov 1;46(9):2014–2018. doi: 10.1002/1097-0142(19801101)46:9<2014::aid-cncr2820460920>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  22. Stetler-Stevenson W. G., Krutzsch H. C., Liotta L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989 Oct 15;264(29):17374–17378. [PubMed] [Google Scholar]
  23. Uría J. A., Ferrando A. A., Velasco G., Freije J. M., López-Otín C. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res. 1994 Apr 15;54(8):2091–2094. [PubMed] [Google Scholar]
  24. Wolf C., Chenard M. P., Durand de Grossouvre P., Bellocq J. P., Chambon P., Basset P. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol. 1992 Dec;99(6):870–872. doi: 10.1111/1523-1747.ep12614846. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES